Novakand Pharma is developing a new class of innovative drugs focusing on inflammatory diseases and cancer.
Novakand Pharma is headquartered at the Karolinska Institute Science Park in Stockholm, Sweden, a world-leading hub for medical research and innovations. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Novakand Pharma is listed on Nasdaq First North Premier.
Novakand Pharma is developing two innovative candidate drugs, both in clinical development phase
Novakand Pharma’s strategy is to develop innovative candidate drugs with solid IP, demonstrate efficacy in human, and based on these results, develop drug candidates into approved pharmaceutical products.
A core component of the business model is to develop and commercialize products by partnering with other pharmaceutical companies where Novakand Pharma out-licenses the development and commercialization rights. This can be out-licensing of either global rights or rights in certain geographies.
The business model includes the possibility for Novakand Pharma to earn revenues from product sales in geographies where the company has retained commercialization rights or in the form of upfront and milestone payments and sales royalties from partners in territories where the company has out-licensed the development and commercialization rights.
Novakand Pharma’s management team has extensive expertise and international experience of translating medical discovery into candidate drugs and developing these into marketed products.
Management
Management
Management
Management
Novakand Pharma's board of directors consists of individuals with extensive experience from senior positions in their respective areas of expertise.
Board
Board
Board
Please contact CEO Peter Selin for any collaboration, business development or licensing enquiries:
Investor relations and enquires from shareholders, news agencies and media are managed by Novakand Pharma’s Communications team. For any IR enquires please contact:
General enquires are managed by Novakand Pharma’s Communications team, please contact: